Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 4
2012 3
2014 2
2015 2
2016 3
2017 2
2018 3
2019 1
2020 4
2021 3
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Saha D, Martuza RL, Rabkin SD. Saha D, et al. Cancer Cell. 2017 Aug 14;32(2):253-267.e5. doi: 10.1016/j.ccell.2017.07.006. Cancer Cell. 2017. PMID: 28810147 Free PMC article.
Glioblastoma is an immunosuppressive, fatal brain cancer that contains glioblastoma stem-like cells (GSCs). Oncolytic herpes simplex virus (oHSV) selectively replicates in cancer cells while inducing anti-tumor immunity. oHSV G47delta expressing murine IL-12 (G47delta-mIL1 …
Glioblastoma is an immunosuppressive, fatal brain cancer that contains glioblastoma stem-like cells (GSCs). Oncolytic herpes simplex viru …
Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.
Wang H, Borlongan M, Hemminki A, Basnet S, Sah N, Kaufman HL, Rabkin SD, Saha D. Wang H, et al. Among authors: saha d. Hum Gene Ther. 2023 Sep;34(17-18):878-895. doi: 10.1089/hum.2023.099. Hum Gene Ther. 2023. PMID: 37578106 Review.
However, IL-2 therapy has significant constraints, including a short serum half-life, low tumor accumulation, and life-threatening toxicities associated with high doses. Oncolytic viruses (OVs) offer a promising option for cancer immunotherapy, selectively targeting and de …
However, IL-2 therapy has significant constraints, including a short serum half-life, low tumor accumulation, and life-threatening toxicitie …
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK, Wakimoto H, Martuza RL, Kaufman HL, Rabkin SD, Saha D. Bommareddy PK, et al. Among authors: saha d. J Immunother Cancer. 2024 Apr 9;12(4):e008880. doi: 10.1136/jitc-2024-008880. J Immunother Cancer. 2024. PMID: 38599661 Free PMC article.
GBMs contain a subpopulation of GBM stem-like cells (GSCs) that play a central role in tumor initiation, progression, and treatment resistance. Oncolytic viruses, especially oncolytic herpes simplex virus (oHSV), replicate selectively in cancer cells and trigger ant …
GBMs contain a subpopulation of GBM stem-like cells (GSCs) that play a central role in tumor initiation, progression, and treatment resistan …
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus.
Nguyen HM, Sah N, Humphrey MRM, Rabkin SD, Saha D. Nguyen HM, et al. Among authors: saha d. J Vis Exp. 2021 May 13;(171):10.3791/62677. doi: 10.3791/62677. J Vis Exp. 2021. PMID: 34057449 Free PMC article.
Oncolytic viruses (OVs), such as the oncolytic herpes simplex virus (oHSV), are a rapidly growing treatment strategy in the field of cancer immunotherapy. ...
Oncolytic viruses (OVs), such as the oncolytic herpes simplex virus (oHSV), are a rapidly growing treatment strategy in the fi …
Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis.
Ghouse SM, Nguyen HM, Bommareddy PK, Guz-Montgomery K, Saha D. Ghouse SM, et al. Among authors: saha d. Front Oncol. 2020 Mar 24;10:384. doi: 10.3389/fonc.2020.00384. eCollection 2020. Front Oncol. 2020. PMID: 32266155 Free PMC article.
Thus, there is an unmet medical need to develop new treatment regimen(s) for TNBC patients. An oncolytic herpes simplex virus encoding a master anti-tumor cytokine, interleukin 12, (designated G47delta-mIL12) selectively kills cancer cells while inducing anti-tumor immunit …
Thus, there is an unmet medical need to develop new treatment regimen(s) for TNBC patients. An oncolytic herpes simplex virus encodin …
Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy.
Borlongan MC, Saha D, Wang H. Borlongan MC, et al. Among authors: saha d. Stem Cell Rev Rep. 2024 Jan;20(1):3-24. doi: 10.1007/s12015-023-10639-6. Epub 2023 Oct 20. Stem Cell Rev Rep. 2024. PMID: 37861969 Review.
Finally, we will highlight pre-clinical and clinical studies that target CSCs within the intricate landscape of the TME, including CAR-T therapy, oncolytic viruses, and CSC-vaccines, with the ultimate goal of uncovering novel avenues for CSC-based cancer immunotherapy....
Finally, we will highlight pre-clinical and clinical studies that target CSCs within the intricate landscape of the TME, including CAR-T the …
Oncolytic herpes simplex virus interactions with the host immune system.
Saha D, Wakimoto H, Rabkin SD. Saha D, et al. Curr Opin Virol. 2016 Dec;21:26-34. doi: 10.1016/j.coviro.2016.07.007. Epub 2016 Aug 3. Curr Opin Virol. 2016. PMID: 27497296 Free PMC article. Review.
Oncolytic viruses (OVs), like oncolytic herpes simplex virus (oHSV), are genetically engineered to selectively replicate in and kill cancer cells, while sparing normal cells. Initial OV infection, cell death, and subsequent OV propagation within the tumor microenvir …
Oncolytic viruses (OVs), like oncolytic herpes simplex virus (oHSV), are genetically engineered to selectively replicate in an …
Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM, Bommareddy PK, Silk AW, Saha D. Nguyen HM, et al. Among authors: saha d. Semin Cancer Biol. 2022 Nov;86(Pt 3):971-980. doi: 10.1016/j.semcancer.2021.05.019. Epub 2021 May 24. Semin Cancer Biol. 2022. PMID: 34033895 Review.
Anti-PD-1 and oncolytic viruses (OVs) have non-overlapping anti-tumor mechanisms, since each agent works at different steps of the cancer-immunity cycle. ...
Anti-PD-1 and oncolytic viruses (OVs) have non-overlapping anti-tumor mechanisms, since each agent works at different steps of the ca …
Porcine reproductive and respiratory syndrome virus (PRRSV) causes apoptosis during its replication in fetal implantation sites.
Karniychuk UU, Saha D, Geldhof M, Vanhee M, Cornillie P, Van den Broeck W, Nauwynck HJ. Karniychuk UU, et al. Among authors: saha d. Microb Pathog. 2011 Sep;51(3):194-202. doi: 10.1016/j.micpath.2011.04.001. Epub 2011 Apr 13. Microb Pathog. 2011. PMID: 21511026
Reproductive failure due to porcine reproductive and respiratory syndrome virus (PRRSV) is characterized by late-term abortions, early farrowing and an increase of dead and mummified fetuses and weak-born piglets. ...PRRSV caused apoptosis in infected cells since 20-61% of …
Reproductive failure due to porcine reproductive and respiratory syndrome virus (PRRSV) is characterized by late-term abortions, earl …
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
Nguyen HM, Guz-Montgomery K, Saha D. Nguyen HM, et al. Among authors: saha d. Cells. 2020 Feb 10;9(2):400. doi: 10.3390/cells9020400. Cells. 2020. PMID: 32050597 Free PMC article. Review.
Oncolytic viruses (OVs) are genetically modified or naturally occurring viruses, which preferentially replicate in and kill cancer cells while sparing healthy cells, and induce anti-tumor immunity. ...In this article, we will discuss safety, tumor-specificity, and a …
Oncolytic viruses (OVs) are genetically modified or naturally occurring viruses, which preferentially replicate in and kill ca …
The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment.
Nguyen HM, Saha D. Nguyen HM, et al. Among authors: saha d. Oncolytic Virother. 2021 Feb 24;10:1-27. doi: 10.2147/OV.S268426. eCollection 2021. Oncolytic Virother. 2021. PMID: 33659221 Free PMC article. Review.
The recent emergence of immuno-virotherapy and FDA approval of T-VEC have generated a great expectation towards oncolytic herpes simplex viruses (oHSVs) as a promising treatment option for GBM. Since the generation and testing of the first genetically engineered oHSV in gl …
The recent emergence of immuno-virotherapy and FDA approval of T-VEC have generated a great expectation towards oncolytic herpes simplex …
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
Saha D, Rabkin SD, Martuza RL. Saha D, et al. J Immunother Cancer. 2020 May;8(1):e000345. doi: 10.1136/jitc-2019-000345. J Immunother Cancer. 2020. PMID: 32457126 Free PMC article.
Because it also modulates the immune system, both beneficially and negatively, understanding how TMZ interacts with immunotherapeutics is important. Oncolytic herpes simplex virus (oHSV) is a new class of cancer therapeutic with both cytotoxic and immunostimulatory activit …
Because it also modulates the immune system, both beneficially and negatively, understanding how TMZ interacts with immunotherapeutics is im …
Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.
Vähä-Koskela M, Tähtinen S, Grönberg-Vähä-Koskela S, Taipale K, Saha D, Merisalo-Soikkeli M, Ahonen M, Rouvinen-Lagerström N, Hirvinen M, Veckman V, Matikainen S, Zhao F, Pakarinen P, Salo J, Kanerva A, Cerullo V, Hemminki A. Vähä-Koskela M, et al. Among authors: saha d. Mol Ther Oncolytics. 2015 Jan 7;1:14006. doi: 10.1038/mto.2014.6. eCollection 2015. Mol Ther Oncolytics. 2015. PMID: 27119097 Free PMC article.
However, repeated injections of the same virus promote antiviral rather than antitumor immunity and tumors may mount innate antiviral defenses to restrict oncolytic virus replication. In this article, we have explored if alternating the therapy virus could ci …
However, repeated injections of the same virus promote antiviral rather than antitumor immunity and tumors may mount innate antiviral …
Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.
Saha D, Rabkin SD. Saha D, et al. Methods Mol Biol. 2020;2058:179-190. doi: 10.1007/978-1-4939-9794-7_11. Methods Mol Biol. 2020. PMID: 31486038 Free PMC article.
Immunohistochemistry (IHC) is an integral laboratory staining technique, which is used for the detection of immune cells in mouse/human tissues or tumors. Oncolytic herpes simplex virus (oHSV) treatment or virotherapy of solid tumors results in antitumor immune responses a …
Immunohistochemistry (IHC) is an integral laboratory staining technique, which is used for the detection of immune cells in mouse/human tiss …
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.
Saha D, Ahmed SS, Rabkin SD. Saha D, et al. Drugs Future. 2015;40(11):739-749. doi: 10.1358/dof.2015.040.11.2383070. Drugs Future. 2015. PMID: 26855472 Free PMC article.
Therefore, novel approaches are needed to improve therapeutic outcomes. Oncolytic viruses (OVs) are excellent candidates as a more effective therapeutic strategy for aggressive cancers like malignant gliomas since OVs have a natural preference or have been genetically engi …
Therefore, novel approaches are needed to improve therapeutic outcomes. Oncolytic viruses (OVs) are excellent candidates as a more ef …
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D, Martuza RL, Rabkin SD. Saha D, et al. Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009. Immunotherapy. 2018. PMID: 30008259 Free PMC article.
Oncolytic viruses, such as oncolytic herpes simplex virus (oHSV), are a new class of cancer therapeutic, which selectively replicate and kill cancer cells, while inducing an inflammatory microenvironment, immunovirotherapy. ...
Oncolytic viruses, such as oncolytic herpes simplex virus (oHSV), are a new class of cancer therapeutic, which selectively rep …
Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of gamma34.5 in Glioblastoma Stem-Like Cells.
Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD. Peters C, et al. Among authors: saha d. J Virol. 2018 Jul 17;92(15):e00246-18. doi: 10.1128/JVI.00246-18. Print 2018 Aug 1. J Virol. 2018. PMID: 29793956 Free PMC article.
Oncolytic viruses, including herpes simplex viruses (HSVs), are a new class of cancer therapeutic engineered to infect and kill cancer cells while sparing normal tissue. ...The difference in degrees of permissivity between GSCs and ScGCs to gamma34.5(-) oHSV illustr …
Oncolytic viruses, including herpes simplex viruses (HSVs), are a new class of cancer therapeutic engineered to infect and kil …
Instability in vitro of a PCV2 infectious clone containing an insertion between ORF1 and ORF2.
Saha D, Doorsselaere JV, Nauwynck HJ. Saha D, et al. Virus Genes. 2012 Apr;44(2):258-61. doi: 10.1007/s11262-011-0693-6. Epub 2011 Nov 25. Virus Genes. 2012. PMID: 22116682
Porcine circovirus 2 (PCV2) is a small circular single-stranded DNA virus that causes postweaning multisystemic wasting syndrome in pigs. ...Viruses from the passage 20 showed deletions of the 60 bp insertion and had extra (+1 to +5) or less (-1 or -2) bp in the int …
Porcine circovirus 2 (PCV2) is a small circular single-stranded DNA virus that causes postweaning multisystemic wasting syndrome in p …
Outcome of experimental porcine circovirus type 1 infections in mid-gestational porcine foetuses.
Saha D, Lefebvre DJ, Ducatelle R, Doorsselaere JV, Nauwynck HJ. Saha D, et al. BMC Vet Res. 2011 Oct 21;7:64. doi: 10.1186/1746-6148-7-64. BMC Vet Res. 2011. PMID: 22018436 Free PMC article.
All other organs of the CCL33-inoculated foetuses and all the organs of the 3384-inoculated foetuses were negative (< 10(1.7) TCID(50)/g tissue) by virus titration. PCV1-positive cells (up to 121 cells/10 mm(2) in CCL33-inoculated foetuses and up to 13 cells/10 mm(2) in …
All other organs of the CCL33-inoculated foetuses and all the organs of the 3384-inoculated foetuses were negative (< 10(1.7) TCID(50)/g …
T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S, Blattner C, Vähä-Koskela M, Saha D, Siurala M, Parviainen S, Utikal J, Kanerva A, Umansky V, Hemminki A. Tähtinen S, et al. Among authors: saha d. J Immunother. 2016 Nov/Dec;39(9):343-354. doi: 10.1097/CJI.0000000000000144. J Immunother. 2016. PMID: 27741089
Using ret transgenic mice that spontaneously develop skin malignant melanoma, we analyzed the mechanism of action of adenoviruses coding for IL2 and TNFalpha in combination with adoptive transfer of TCR-transgenic TRP-2-specific T cells. Following T-cell therapy and intratumoral …
Using ret transgenic mice that spontaneously develop skin malignant melanoma, we analyzed the mechanism of action of adenoviruses coding for …
Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL. Saha D, et al. Clin Cancer Res. 2018 Jul 15;24(14):3409-3422. doi: 10.1158/1078-0432.CCR-17-1717. Epub 2018 Mar 29. Clin Cancer Res. 2018. PMID: 29599413 Free PMC article.
Therefore, we developed a strategy to target the complex GBM microenvironment, including GSCs and tumor vasculature.Experimental Design: We evaluated the cytotoxic effects of VEFGR tyrosine kinase inhibitor (TKI) axitinib in vitro and then tested antitumor efficacy of axitinib in …
Therefore, we developed a strategy to target the complex GBM microenvironment, including GSCs and tumor vasculature.Experimental Design: We …
Unusual outcome of in utero infection and subsequent postnatal super-infection with different PCV2b strains.
Saha D, Karniychuk UU, Huang L, Geldhof M, Vanhee M, Lefebvre DJ, Meerts P, Ducatelle R, Doorsselaere JV, Nauwynck HJ. Saha D, et al. Virol Sin. 2014 Jun;29(3):176-82. doi: 10.1007/s12250-014-3431-0. Epub 2014 Jun 17. Virol Sin. 2014. PMID: 24950783 Free PMC article.
VC2002, isolated from postweaning multisystemic wasting syndrome (PMWS)-affected pig, is a mixture of two porcine circovirus genotype 2b (PCV2b) viruses, K2 and K39. Preliminary experiments disclosed short-term adverse effects of K39, but not K2, on porcine foetuses. ...
VC2002, isolated from postweaning multisystemic wasting syndrome (PMWS)-affected pig, is a mixture of two porcine circovirus genotype 2b (PC …
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A. Siurala M, et al. Among authors: saha d. Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Mol Ther. 2016. PMID: 27357626 Free PMC article.
Armed adenoviruses expressed high local and low systemic levels of cytokine when injected into B16.OVA tumors, suggesting safety of virus-mediated cytokine delivery. Antitumor efficacy was significantly enhanced with adenoviruses coding for murine interleukin-2 (mIL-2) and …
Armed adenoviruses expressed high local and low systemic levels of cytokine when injected into B16.OVA tumors, suggesting safety of virus …
Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma.
Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D. Bommareddy PK, et al. Among authors: saha d. J Biol Methods. 2019;6(2):e112. doi: 10.14440/jbm.2019.281. Epub 2019 Apr 4. J Biol Methods. 2019. PMID: 31123687 Free PMC article.
Multi-color flow cytometry is a standard laboratory protocol, which is regularly used to analyze tumor-infiltrating immune cell subsets. Oncolytic herpes simplex virus has shown promise in treating various types of cancers, including deadly glioblastoma. Intracranial/intra …
Multi-color flow cytometry is a standard laboratory protocol, which is regularly used to analyze tumor-infiltrating immune cell subsets. Onc …